Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials
570
Staphylococcus aureus
Science
Molecular Biology/Biochemistry [q-bio.BM]
[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry
[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology
Article
Mice
03 medical and health sciences
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN]
Drug Resistance, Bacterial
Acyl-Carrier Protein S-Malonyltransferase
Fatty Acid Synthase, Type II
Animals
[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM]
Cloning, Molecular
[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM]
Alleles
Molecular Biology/Genomics [q-bio.GN]
Mice, Inbred BALB C
0303 health sciences
Polymorphism, Genetic
Virulence
Escherichia coli Proteins
Lipogenesis
Q
Fatty Acids
Genetic Complementation Test
[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology
Sequence Analysis, DNA
[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology
Triclosan
Molecular Biology/Molecular biology
Anti-Bacterial Agents
3. Good health
[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry
[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry
Mutation
[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN]
Female
[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology
DOI:
10.1038/ncomms12944
Publication Date:
2016-10-05T10:10:15Z
AUTHORS (12)
ABSTRACT
AbstractThe bacterial pathway for fatty acid biosynthesis, FASII, is a target for development of new anti-staphylococcal drugs. This strategy is based on previous reports indicating that self-synthesized fatty acids appear to be indispensable for Staphylococcus aureus growth and virulence, although other bacteria can use exogenous fatty acids to compensate FASII inhibition. Here we report that staphylococci can become resistant to the FASII-targeted inhibitor triclosan via high frequency mutations in fabD, one of the FASII genes. The fabD mutants can be conditional for FASII and not require exogenous fatty acids for normal growth, and can use diverse fatty acid combinations (including host fatty acids) when FASII is blocked. These mutants show cross-resistance to inhibitors of other FASII enzymes and are infectious in mice. Clinical isolates bearing fabD polymorphisms also bypass FASII inhibition. We propose that fatty acid-rich environments within the host, in the presence of FASII inhibitors, might favour the emergence of staphylococcal strains displaying resistance to multiple FASII inhibitors.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (67)
CITATIONS (58)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....